Galectin Therapeutics to Present at Upcoming Conferences

Jan. 28, 2016 8:03 am |  More About Galectin Therapeutics


NORCROSS, Ga., Jan. 28, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today Peter G. Traber, MD, the Company’s president, chief executive officer and chief medical officer will present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016, at 10:30 a.m. and at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference on February 11, 2016, at 12:00 p.m. Eastern Standard Time.

The BIO CEO presentation will be webcast, and may be found on the company’s website at www.galectintherapeutics.com.

About Galectin Therapeutics

Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

About BIO CEO & Investor Conference

The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.

https://www.bio.org/events/conferences/bio-ceo-investor-conference

About Source Capital Group

Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client’s needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. It has grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to its investment banking activity. http://www.sourcegrp.com/

Contacts
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com

LHA
Kim Golodetz
(212) 838-3777
kgolodetz@lhai.com

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.

 

Primary Logo

GlobeNewswire
January 28, 2016 - 8:03 AM EST


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market